Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 5/20 | 0.47 |
| ▸ | BACE1 | P56817 | 3/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11043050 | 1.00 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSL | |
| SCHEMBL10535982 | 1.00 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSL | |
| SCHEMBL11137675 | 1.00 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSL | |
| SCHEMBL6519145 | 1.00 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSL | |
| SCHEMBL7828875 | 1.00 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSL | |
| SCHEMBL10537924 | 0.87 | REN (0.57) | CA1CA2CA7CYP2D6REN | |
| SCHEMBL10977303 | 0.87 | CA1 (0.53) | CA1CA2CA7CYP2D6REN | |
| SCHEMBL764842 | 0.87 | REN (0.57) | CA1CA2CA7CYP2D6REN | |
| SCHEMBL8270788 | 0.86 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSL | |
| SCHEMBL10573647 | 0.85 | CA1 (0.51) | CA1CA2CA7CYP2D6REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276484-B2 | Dipeptide inhibitors of β-secretase | ELAN PHARMACEUTICALS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276484-B2 | Dipeptide inhibitors of β-secretase | ELAN PHARMACEUTICALS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-7238774-B2 | Statine derivatives for the treatment of Alzheimer's disease III | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-03 | — | — | US | disclosed |
| WO-2006050862-A1 | STATINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-18 | — | — | WO | disclosed |
| US-20060100158-A1 | Statine derivatives for the treatment of Alzheimer's disease III | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
| CN-1390232-A | Human beta-secretase enzyme, inhibitor, and its composition and use | ELAN PHARM INC (US) | 2003-01-08 | — | — | CN | disclosed |
| EP-0258289-A4 | PEPTIDE ANALOGS | — | 1991-01-02 | — | — | EP | disclosed |
| US-4816598-A | 4-Amino-butanoic acid derivatives | SANOFI (FR) | 1989-03-28 | — | — | US | disclosed |
| EP-0258289-A1 | PEPTIDE ANALOGS | ABBOTT LABORATORIES (US) | 1988-03-09 | — | — | EP | disclosed |
| US-4698329-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1987-10-06 | — | — | US | disclosed |
| WO-1987004349-A1 | PEPTIDE ANALOGS | DELLARIA JOSEPH | 1987-07-30 | — | — | WO | disclosed |
| EP-0184855-A2 | Resin inhibiting compounds | ABBOTT LABORATORIES (US) | 1986-06-18 | — | — | EP | disclosed |
| EP-0152255-A2 | New renin-inhibitory peptides and their use | SANKYO COMPANY LIMITED (JP) | 1985-08-21 | — | — | EP | disclosed |
| US-4397786-A | Method of preparing statine and derivatives | MERCK & CO., INC. (US) | 1983-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100158-A1 | Statine derivatives for the treatment of Alzheimer's disease III | HMGCR, LDLR, PCSK9 | CA1 3277/4885CA2 4584/4885CA7 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.